Royalty Pharma Analyst Price Targets - Benzinga

Royalty Pharma PLC

RPRXNASDAQ

Trade with Public

Trade with Public

$60.85

-1.07-1.73%

가까이에: Aug 28, 5:00 PM EST

$60.75

-0.10-0.16%

시간외: 7:14 PM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

Royalty Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Royalty Pharma (RPRX).

Price Target Range — 10 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$54Upside to Avg. PT-11.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$58→$62
Jul 13, 2026	TD Cowen	Steve Scala	PT Raise	Buy	$50→$65
May 7, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$66
May 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$50→$58
Apr 21, 2026	UBS	Ashwani Verma	PT Raise	Buy	$51→$57
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$61→$63
Jan 30, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$38→$49
Jan 27, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$48→$50
Dec 11, 2025	TD Cowen	Steve Scala	PT Raise	Buy	$42→$45
Oct 10, 2025	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$55→$54
Sep 30, 2025	Goldman Sachs	Asad Haider	Initiate	Buy	$42
Jul 22, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$40→$42
Jul 10, 2025	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$51→$54
Oct 25, 2024	Citigroup	Andrew Baum	PT Cut	Buy	$60→$40
Aug 14, 2024	Goldman Sachs	Chris Shibutani	PT Raise	Buy	$50→$51
Jul 11, 2024	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$48→$51
Jun 3, 2024	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$28
Apr 12, 2024	B of A Securities	Geoff Meacham	PT Cut	Buy	$40→$38
Feb 20, 2024	JP Morgan	Chris Schott	PT Cut	Overweight	$45→$42
Feb 20, 2024	Goldman Sachs	Chris Shibutani	PT Cut	Buy	$56→$50

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $66.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $50 to $58.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $63

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $61 to $63.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $50

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $48 to $50.

Benzinga Newsdesk